Hege KM, Jooss K, Pardoll D. GM-CSF Gene-Modified Cancer Cell Immunotherapies: Of Mice and Men. International Reviews of Immunology, Vol. 25, pp: 321-352 (2006).
Simons JW, Sacks N. Granulocyte-Macrophage Colony-Stimulating Factor-Transduced Allogeneic Cancer Cellular Immunotherapy: The GVAX™ Vaccine for Prostate Cancer. Urologic Oncology: Seminars and Original Investigations, Vol. 24, pp: 419-424 (2006).
Simons JW, Carducci MA, Mikhak B, Lim M, Biedrzycki B, Borellini F, Clift SM, Hege KM, Ando DG, Piantadosi S, Mulligan R, Nelson WG. Phase I/II Trial of an Allogeneic Cellular Immunotherapy in Hormone-Naïve Prostate Cancer. Clinical Cancer Research, Vol. 12, No. 11, pp: 3394-3401 (2006).
Morck Thomas A, Santarsiero LM, Lutz ER, Armstrong TD, Chen Y-C, Huang L-Q, Laheru DA, Goggins M, Hruban RH, Jaffee EM. Mesothelin-specific CD8+T Cell Responses Provide Evidence of In Vivo Cross-Priming by Antigen-Presenting Cells in Vaccinated Pancreatic Cancer Patients. The Journal of Experimental Medicine, Vol. 200, No. 3, pp: 297-306, (2004).
Nemunaitis J, Sterman D, Jablons D, SmithII J, Fox B, Maples P, Hamilton S, Borellini F, Lin A, Morali S, Hege K. Granulocyte-Macrophage Colony-Stimulating
Factor Gene-Modified Autologous Tumor Vaccines in Non-Small-Cell Lung Cancer.
Journal of the National Cancer Institute, Vol. 96, No. 4, pp: 326-331,
(2004).
Salgia R, Lynch T, Skarin A, Lucca J, Lynch C, Jung K, Hodi FS, Jaklitsch M,
Mentzer S, Swanson S, Lukanich J, Bueno R, Wain J, Mathisen D, Wright C, Fidias
P, Donahue D, Clift S, Hardy S, Neuberg D, Mulligan R, Webb I, Sugarbaker D,
Mihm M, Dranoff G. Vaccination with irradiated autologous tumor cells engineered
to secrete granulocyte-macrophage colony-stimulating factor augments antitumor
immunity in some patients with metastatic non-small-cell lung carcinoma. Journal
of Clinical Oncology, 21(4), pp: 624-30 (2003).
Yu DC, Working P, and Ando D. Selectively replicating oncolytic adenoviruses
as cancer therapeutics. Current Opinion in Molecular Therapeutics, 4(5),
pp: 435-443 (2002).
Zhang J., Ramesh N., Chen Y., Li Y., Dilley J., Working P., Yu D.C. Identification
of Human Uroplakin II Promoter and its use in the Construction of CG8840, a
Urothelium-specific Adenovirus Variant that Eliminates Established Bladder Tumors
in Combination with Docetaxel. Cancer Research, Vol. 62, pp: 3743-3750
(2002).
DeWeese,T.L., van Der Poel, H., Li, S., Mikhak, B., Drew, R., Goemann, M., Hamper,
U., DeJong, R., Detorie, N., Rodrigues, R., Haulk, T., DeMarzo, A.M., Piantadosi,
S., Yu, D.C., Chen, Y., Henderson, D.R., Carducci, M.A., Nelson, W.G., Simons,
J.W. A phase I trial of CV706, a replication-competent, PSA selective oncolytic
adenovirus, for the treatment of locally recurrent prostate cancer following
radiation therapy. Cancer Research, Vol.61, No. 20, pp: 7464-72 (2001).
Li, Y., Yu, D.C., Chen, Y., Amin, P., Zhang, H., Nguyen, N., Henderson, D.R.
A Hepatocellular Carcinoma-specific Adenovirus Variant, CV890, Eliminates Distant
Human Liver Tumors in Combination with Doxorubicin. Cancer Research,
Vol. 61, No. 17, pp: 6428-6436 (2001).
Chen, Y., DeWeese, T., Dilley, J., Zhang, Y., Li, Y., Ramesh, N., Lee, J., Pennathur-Das,
R., Radzyminski, J., Wypch, J., Brignetti, D., Scott, S., Stephens, J., Karpf,
D.B., Henderson, D.R., Yu, D.C. CV706, a Prostate Cancer-specific Adenovirus
Variant, in Combination with Radiotherapy Produces Synergistic Antitumor Efficacy
without Increasing Toxicity. Cancer Research, Vol. 61, No. 17, pp: 5453-5460
(2001).
Jaffee, E., Hruban, R., Biedrzycki, B., Laheru, D., Schepers, K., Sauter, P.,
Goemann, M., Coleman, J., Grochow, L., Donehower, R., Lillemoe, K., O'Reilly,
S., Abrams, R., Pardoll, D., Cameron, J., Yeo, C. Novel allogeneic granulocyte-macrophage
colony stimulating factor-secreting tumor vaccine for pancreatic cancer: A Phase
I trial of safety and immune activation. Journal of Clinical Oncology,
Vol. 19, No. 1, pp: 145-156 (2001).
Yu, D., Dilley, J., Li, Y., Embry, M., Zhang, H., Nguyen, N., Amin, P., Oh,
J. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel
and docetaxel. Cancer Research, Vol. 61, No. 2, pp: 517-525 (2001).
Borrello, I., Sotomayor, E., Rattis, F-M., Cooke, S., Gu, L., Levitsky, H. Sustaining
the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage
colony-stimulating factor (GM-CSF)-producing tumor vaccines. Blood, Vol.
95, No. 10, pp: 3011-3019 (2000).
Simons, J., Mikhak, B., Chang, J., DeMarzo, A., Carducci, M., Lim, M., Weber,
C., Baccala, A., Goemann, M., Clift, S., Ando, D., Levitsky, H., Cohen, L.,
Sanda, M., Mulligan, R., Partin, A., Carter, H., Piantadosi, S., Marshall, F.,
Nelson, W. Induction of immunity to prostate cancer antigens: Results of a clinical
trial of vaccination with irradiated autologous prostate tumor cells engineered
to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene
transfer. Cancer Research, No. 59, pp: 5160-5168 (1999).
Soiffer, R., Lynch, T., Mihm, M., Jung, K., Rhuda, C., Schmollinger, J., Hodi,
F., Liebster, L., Lam, P., Mentzer, S., Singer, S., Tanabe, K., Cosimi, B.,
Duda, R., Sober, A., Bhan, A., Daley, J., Neuberg, D., Parry, G., Rokovich,
J., Richards, L., Drayer, J., Berns, A., Clift, S., Cohen, L., Mulligan, R.,
Dranoff, G. Vaccination with irradiated autologous melanoma cells engineered
to secrete human granulocyte-macrophage colony-stimulating factor generates
potent antitumor immunity in patients with metastatic melanoma. Proceedings
of the National Academy of Sciences, Vol. 95, pp: 13141-13146 (1998).
Rodriguez, Ron, Schuur, Eric R., Lim, Ho Yeong, Henderson, Gail A., Simons,
Jonathan W., Henderson, Daniel R. Prostate Attenuated Replication Competent
Adenovirus (ARCATM) CN706: A Selective Cytotoxic for Prostate-Specific Antigen-Positive
Prostate Cancer Cells. Cancer Research, Vol. 57, No. 13, pp: 2559-2563,
(1997).
Hardy, S., Kitamura, M., Harris-Stansil, T., Dai, Y., Phipps, M.L. Construction
of adenovirus vectors through cre-lox recombination. Journal of Virology,
Vol. 71, No. 3, pp: 1842-1849 (1997).
Wang, Q., Greenburg G., Bunch, D., Farson, D., Finer, M.H. Persistent transgene
expression in mouse liver following in vivo transfer with a DE1/DE4 adenovirus
vector. Gene Therapy, Vol. 4, No. 5, pp: 393-400 (1997).
Wang, Q., Finer, M. Second-generation adenovirus vectors. Nature Medicine,
Vol. 2, No. 4, pp: 714-716 (1996).
Wang, Q., Jia X.-C., Finer, M. A packaging cell line for propagation of recombinant
adenovirus vectors containing two lethal gene-region deletions. Gene Therapy,
pp: 775-783 (1995).
Dranoff G., Jaffee E., Lazenby A., Golumbek P., Levitsky H., Brose K., Jackson
V., Hamada H., Pardoll D., Mulligan R.C. Vaccination with irradiated tumor cells
engineered to secrete murine granulocyte-macrophage colony-stimulating factor
stimulates potent, specific, and long-lasting anti-tumor immunity. Proceedings
of the National Academy of Science, Vol. 90, No. 8, pp: 3539-43 (1993). |
